Patients with lymphoma or other lymphoid cancers should continue to take steps to protect themselves from COVID-19 even if they have been vaccinated against the disease, a new study led by investigators at Dana-Farber Cancer ...
Aug 23, 2021
0
101
An immune system drug may help prevent or slow complications in a type of multiple sclerosis known as secondary progressive MS, a new study finds.
Jan 9, 2019
0
37
(HealthDay) -- Repeated and prolonged use of rituximab for B-cell depletion to treat relapses or maintain remission is safe and effective in patients with refractory granulomatosis with polyangiitis (GPA; Wegener's), a primary ...
Jul 2, 2012
0
0
(HealthDay)—Vitamin D deficiency (VDD) contributes to worse outcomes in elderly patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab, according to a study published online Aug. 18 in the Journal of ...
Aug 27, 2014
0
0
(HealthDay)—For patients with secondary progressive multiple sclerosis (SPMS), treatment with rituximab is associated with a significantly lower Expanded Disability Status Scale (EDSS) score and delayed progression, according ...
Jan 8, 2019
0
2
Results from an multi-institutional, phase 3 clinical trial show that older patients with chronic lymphocytic leukemia (CLL) have a significantly lower rate of disease progression if treated with the newer targeted drug, ...
Dec 3, 2018
0
25
Administering the drug rituximab once weekly for one month provides the same benefits as 18 months of daily immunosuppressive therapy in people with severe forms of vasculitis, or inflammation of the blood vessels, a study ...
Jul 31, 2013
0
1
Multiple sclerosis (MS) patients treated with Rituximab have better responses to the COVID-19 vaccine if they have higher B cell counts. This is the finding of a study from Uppsala University published in the journal JAMA ...
May 12, 2022
0
65
The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) today announced results from an extended follow-up analysis of patients in its randomized Phase 3 clinical trial, E1912. The results show that the combination of ibrutinib, ...
Dec 7, 2019
0
4
(HealthDay)—Rituximab plus lenalidomide has similar efficacy to rituximab plus chemotherapy among patients with previously untreated follicular lymphoma, according to a study published in the Sept. 6 issue of the New England ...
Sep 12, 2018
0
0
